Role of stem cell transplantation in multiple myeloma in the era of novel agents

VernacularTitle:新药时代造血干细胞移植在多发性骨髓瘤治疗中的地位
Author: Nian LIU ; Wenming CHEN
Publication Type:Journal Article
Keywords: Multiple myeloma; Autologous hematopoietic stem cell transplantation; Hematopoietic stem cell transplantation,allogeneic
From: Journal of Leukemia & Lymphoma 2013;22(6):343-347
CountryChina
Language:Chinese
Abstract: Autologous stem cell transplantation (ASCT) has been considered as frontline therapy for patients with multiple myeloma (MM) based on the increased rate of response and prolonged progression-free survival compared with conventional chemotherapy.In the recent years,the favorable results shown by newdrug-based multidrug inductions,consolidations,and long-term maintenance approaches have challenged the role of ASCT.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has shown to be a potentially curative treatment for MM.However,the effectiveness of high-dose conditioning with conventional allo-HSCT is compromised by transplant-related mortality (TRM).Nonmyeloablative transplantation has showed reduced TRM and promising graft-versus-myeloma effects,but rates of acute and chronic graft-versus-host disease remain high.This article provides an overview of clinical trials and aims to define the role of stem cell transplantation in the era of novel agents.